SGLT2i

ApprovedSmall molecule

UUniversity of Chicago

SGLT2i is one of 52 small molecule programs targeting Heart Failure. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Type 2 DiabetesActive, not recruiting

KidneyNot yet recruiting

Heart FailureApproved

Active, not recruiting

Type 2 DiabetesPreclinical

Active, not recruiting

KidneyPhase 2

Not yet recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

SGLT2i

UUniversity of Chicago

Approved

2 2

Glargine

Eli Lilly

Preclinical

8 3

Aurlumyn

BBTG International Inc.

Preclinical

1 4

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 5

Forxiga

AstraZeneca

Preclinical

3 6

Lovaza

AstraZeneca

Preclinical

1 7

Acipimox

Boehringer Ingelheim

Preclinical

2 8

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 9

GLP-1

RRigshospitalet, Denmark

Preclinical

1 10

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Not yet recruiting

Kidney

NCT07682350

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity

Completed·AAna Palanca··NCT05535322·26,944 enrolled

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Completed·KKaiser Permanente··NCT05073692·241,981 enrolled

Heart Failure1 trial

The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

Terminated·UUniversity of Chicago·Phase 4·NCT05346653·1 enrolled

TED1 trial

HF Patients With LVADs Being Treated With SGLT2i

Completed·UUniversity of Chicago·Phase 4·NCT05278962·32 enrolled

Transplant Recipient1 trial

Impact of SGLT2 Inhibitors in Heart Transplant Recipients

Enrolling by invitation·UUniversidade Federal do Ceara·Phase 2·NCT06147271·80 enrolled

Kidney1 trial

SGL-TX-PTDM: SGLT2i Effect on PTDM Development and Kidney Allograft Function in Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial

Not yet recruiting·OOdense University Hospital·Phase 2·NCT07682350·184 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for SGLT2i. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SGLT2i compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SGLT2i. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Chicago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Chicago

SGLT2i

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Type 2 Diabetes2 trials

Heart Failure1 trial

TED1 trial

Transplant Recipient1 trial

Kidney1 trial

References

Drug Info

Quick Facts

Related News